Story perspectives

CRL Partners in Oncology Research, Stock Soars 4.2%

9/14/2025

47 4

Summary

Story summary

Charles River Laboratories (CRL) formed two collaborations to advance oncology research, partnering with the Parker Institute for Cancer Immunotherapy and supporting Phase I Clinical Trials at Children’s Hospital Los Angeles.
Following the announcement, CRL's stock rose 4.2% to $159.74, with a market cap of $7.86 billion.
The global oncology market is expected to grow from $225.01 billion in 2024 to $668.26 billion by 2034.
CRL recently integrated Akadeum's T Cell Isolation Kit into its Cell Therapy Flex Program.
Over the past three months, CRL shares have increased 5.2%, outperforming the industry.

1 of 1

Story summary

Charles River Laboratories (CRL) formed two collaborations to advance oncology research, partnering with the Parker Institute for Cancer Immunotherapy and supporting Phase I Clinical Trials at Children’s Hospital Los Angeles.
Following the announcement, CRL's stock rose 4.2% to $159.74, with a market cap of $7.86 billion.
The global oncology market is expected to grow from $225.01 billion in 2024 to $668.26 billion by 2034.
CRL recently integrated Akadeum's T Cell Isolation Kit into its Cell Therapy Flex Program.
Over the past three months, CRL shares have increased 5.2%, outperforming the industry.